MAPT and Alzheimer disease: Positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) measures of Aβ, occasionally in conjunction with studies of CSF tau forms, are currently the gold standards for diagnosing AD (Brand et al., 2022).